MRK Merck & Co., Inc.

Price (delayed)

$79.21

Market cap

$200.34B

P/E Ratio

19.18

Dividend/share

$2.44

EPS

$4.13

Enterprise value

$220.11B

Sector: Healthcare
Industry: Drug Manufacturers - General
Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the company's relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Highlights

The P/E is 55% lower than the 5-year quarterly average of 42.4 and 10% lower than the last 4 quarters average of 21.3
MRK's quick ratio is up by 27% since the previous quarter and by 12% year-on-year
MRK's debt is up by 16% year-on-year and by 10% since the previous quarter

Key stats

What are the main financial stats of MRK
Market
Shares outstanding
2.53B
Market cap
$200.34B
Enterprise value
$220.11B
Valuations
Price to earnings (P/E)
19.18
Price to book (P/B)
7.23
Price to sales (P/S)
4.24
EV/EBIT
17.65
EV/EBITDA
13.65
EV/Sales
4.66
Earnings
Revenue
$47.19B
EBIT
$12.47B
EBITDA
$16.12B
Free cash flow
$9.34B
Per share
EPS
$4.13
Free cash flow per share
$3.7
Book value per share
$10.95
Revenue per share
$18.7
TBVPS
$21.39
Balance sheet
Total assets
$90.62B
Total liabilities
$62.87B
Debt
$30.87B
Equity
$27.64B
Working capital
$7.17B
Liquidity
Debt to equity
1.12
Current ratio
1.32
Quick ratio
0.84
Net debt/EBITDA
1.23
Margins
EBITDA margin
34.2%
Gross margin
70.1%
Net margin
22.2%
Operating margin
25.4%
Efficiency
Return on assets
12.2%
Return on equity
39.3%
Return on invested capital
26%
Return on capital employed
18.2%
Return on sales
26.4%
Dividend
Dividend yield
3.08%
DPS
$2.44
Payout ratio
59.1%

MRK stock price

How has the Merck stock price performed over time

Financial performance

How have Merck's revenue and profit performed over time
Revenue
$47.19B
Gross profit
$33.06B
Operating income
$11.99B
Net income
$10.48B
Gross margin
70.1%
Net margin
22.2%
The net income is up by 12% year-on-year and by 3.3% since the previous quarter
The gross profit has grown by 7% year-on-year
The revenue has grown by 6% YoY
MRK's net margin is up by 5% since the previous quarter and by 5% year-on-year

Growth

What is Merck's growth rate over time

Valuation

What is Merck stock price valuation
P/E
19.18
P/B
7.23
P/S
4.24
EV/EBIT
17.65
EV/EBITDA
13.65
EV/Sales
4.66
The P/E is 55% lower than the 5-year quarterly average of 42.4 and 10% lower than the last 4 quarters average of 21.3
The EPS has grown by 15% YoY and by 3.8% from the previous quarter
The price to book (P/B) is 29% higher than the 5-year quarterly average of 5.6 but 8% lower than the last 4 quarters average of 7.9
Merck's equity has increased by 5% from the previous quarter
The revenue has grown by 6% YoY
MRK's P/S is 6% below its last 4 quarters average of 4.5

Efficiency

How efficient is Merck business performance
Merck's ROE has increased by 20% YoY and by 3.1% from the previous quarter
The ROIC rose by 12% YoY
The company's return on assets rose by 9% YoY
The ROS has grown by 3.5% from the previous quarter

Dividends

What is MRK's dividend history
DPS
$2.44
Dividend yield
3.08%
Payout ratio
59.1%
Recent dividends

Financial health

How did Merck financials performed over time
The total assets is 44% more than the total liabilities
MRK's quick ratio is up by 27% since the previous quarter and by 12% year-on-year
The current ratio has grown by 19% from the previous quarter and by 9% YoY
MRK's debt is 12% greater than its equity
The debt to equity has grown by 17% YoY and by 4.7% from the previous quarter
MRK's debt is up by 16% year-on-year and by 10% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.